Read our latest news, and find more about us and our portfolio companies.

Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors

STORM Therapeutics Expands R&D Leadership Team

TORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fyfe as Senior Vice President of Therapeutics and the promotion of Beth Thomas to Vice President of Medicinal Chemistry.

Synaffix Enters $2 Billion License Agreement with Amgen

- Total potential deal value up to $2 billion plus tiered royalties on commercial sales - Synaffix to provide Amgen access to its proprietary antibody-drug conjugate (ADC) technologies

IOnctura Provides Development Update On First-In-Class Semi-Allosteric PI3Kδ Inhibitor Program

- Updated clinical data demonstrates a prolonged and sustained favorable safety profile for roginolisib (IOA-244) - Clinical data shows a comparable safety profile in both solid and hematologic malignancies - Clinical responses seen in both solid and hematologic malignancies - US FDA grants Orphan Drug Designation for IOA-244 in uveal melanoma

Hummingbird Bioscience and Synaffix Enter $150m License Agreement

Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

IMT-009 targets novel checkpoint CD161, restores activation of T and NK cells in preclinical model